Clinical Trial Update: A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating CLAG with imatinib (Gleevec) for refractory/relapsed chronic myeloid leukemia and acute myeloid leukemia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Chronic Myeloid Leukemia

Drugs mentioned

• CYTARABINE (CYTARABINE)
• Cladribine (cladribine)
• Filgrastim (filgrastim)
• Gleevec (Imatinib)

Snippet

Sponsor: University of Cincinnati | Conditions: Chronic Myeloid Leukemia, Blast Crisis, Acute Myeloid Leukemia | Phase 2 | Status: WITHDRAWN